BNET Industries
AtheroGenics Inc. (AGIX Q) is in the Pharma Industry
Latest News and Analysis
AtheroGenics Receives Delisting Notice From NASDAQ Global Market Due to Chapter 11 Filing
AtheroGenics, Inc. (NASDAQ: AGIX) today reported that it received notification from the Nasdaq Stock Market indicating that the staff of the Nasdaq Stock Market had determined, in accordance with NASDAQ Marketplace Rules 4300, 4450f and IM-4300, that the Company's common stock should be delisted from the Nasdaq Global Market in...
Zacks Analyst Blog Highlights: Wipro, Ltd., Skechers USA, Inc., Coca-Cola Hellenic Bottling Co., Scientific Games Corp. and AtheroGenics, Inc
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Wipro, Ltd. (NYSE: WIT), Skechers USA, Inc. (NYSE: SKX), Coca-Cola Hellenic...
Zacks Analyst Blog Highlights: Toyota Motor Corp., Jamba, Inc., AtheroGenics, Inc., Vodafone Group Plc. and Xilinx, Inc
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Toyota Motor Corp. (NYSE: TM), Jamba, Inc. (Nasdaq: JMBA), AtheroGenics, Inc....
AtheroGenics Seeks to Realign Capital Structure
AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today reported that it will not repay the Company's 4.5% Convertible Notes (the "2008 Notes," CUSIP 047439AB0) due today, nor will it make its scheduled interest payment on the 2008 Notes or the 4.5% Convertible...
AtheroGenics Receives Notice of Non-Compliance With Listing Requirement for the NASDAQ Global Market
AtheroGenics, Inc. (NASDAQ: AGIX), today reported that it received a Staff Determination Letter from the NASDAQ Listing Qualifications Department indicating that the Company has not regained compliance with the $1.00 per share bid price requirement for continued listing set forth in Marketplace Rule 4450b(4). As a result, shares of the...
/ CORRECTION - AtheroGenics to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2008
In the news release "AtheroGenics to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2008," issued earlier today by AtheroGenics, Inc. (NASDAQ: AGIX), we are advised by the company that the time of the webcast in paragraph one should read "11:10 a.m. EDT" rather than...
AGT, SGN, AGIX, CHTP, SOLM, BZLFY Have Been Removed From Naked Short List Today.
M2 PRESSWIRE-1 April 2008-BUYINS.NET: AGT, SGN, AGIX, CHTP, SOLM, BZLFY Have Been Removed From Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:01042008 BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short...
IRE, LFC, RHD, AGIX, AMGI, CEDU Have Also Been Added To Naked Short List Today.
M2 PRESSWIRE-14 March 2008-BUYINS.NET: IRE, LFC, RHD, AGIX, AMGI, CEDU Have Also Been Added To Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:14032008 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked...
Stock News You Can Use: ASWRF, AGIX, TLPE.
M2 PRESSWIRE-4 March 2008-Businessnetwire.us: Stock News You Can Use: ASWRF, AGIX, TLPEC1994-2008 M2 COMMUNICATIONS LTD RDATE:04032008 New York, NY -- Anglo Swiss Resources Inc. (OTCBB: ASWRF); AtheroGenics, Inc. (NASDAQ: AGIX); TelePlus World, Corp. (OTCBB: TLPE) BusinessNetWire...
Emerging Markets Consulting, LLC. : Emerging Equity Alerts.
M2 PRESSWIRE-4 March 2008-Emerging Markets Consulting, LLC.: Emerging Markets Consulting, LLC. : Emerging Equity AlertsC1994-2008 M2 COMMUNICATIONS LTD RDATE:04032008 Orlando, FL -- Stocks gaining traction in yesterday's trading were Diebold, Incorporated, (NYSE: DBD), Converted Organics, Inc., (NASDAQ: COIN),...
ABR, SBR, TWP, AGIX, CNLG, NSTK Have Been Removed From Naked Short List Today.
M2 PRESSWIRE-3 March 2008-BUYINS.NET: ABR, SBR, TWP, AGIX, CNLG, NSTK Have Been Removed From Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:03032008 BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short...
AtheroGenics Inc Q4 2007 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions Thank you. Our first question comes from the line of Leah Hartman with CRT Capital. Please proceed with your question. Leah Hartman - CRT Capital Good morning and thank you for taking my call. I did want to focus on the interim data announcement that...
Afternoon Investor Focus.
M2 PRESSWIRE-4 January 2008-Businessnetwire.us: Afternoon Investor FocusC1994-2008 M2 COMMUNICATIONS LTD RDATE:03012008 New York, NY -- BusinessNetWire's "Investor's Update" Focuses on the Following Companies: AtheroGenics, Inc. (NASDAQ: AGIX); Wi-Fi TV Inc. (PINKSHEETS: WTVN); Asia Properties, Inc....
AtheroGenics to Present at JPMorgan Healthcare Conference on January 10, 2008
AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer, will be presenting a company overview and update at the upcoming 26th Annual JPMorgan Healthcare Conference on Thursday, January 10, 2008, at...
AtheroGenics Receives Notice of Non-Compliance With Listing Requirement for NASDAQ Global Market
AtheroGenics, Inc. (NASDAQ: AGIX) today reported that it received a Staff Determination Letter from the NASDAQ Listing Qualification Department indicating that the Company has not regained compliance with the continued listing requirements of the NASDAQ Global Market because the market value of the Company's listed securities has fallen below $50...
Afternoon Stock News For January 2, 2008.
M2 PRESSWIRE-2 January 2008-Businessnewsnow.us: Afternoon Stock News For January 2, 2008C1994-2008 M2 COMMUNICATIONS LTD RDATE:02012008 New York, NY -- BusinessNewsNow's Stock News Highlights: Brown & Brown, Inc. (NYSE: BRO); AtheroGenics, Inc. (NASDAQ: AGIX); Franklin Mining, Inc....
AtheroGenics Announces New ARISE Diabetes Data on AGI-1067 Presented at the European Society of Cardiology Congress 2007
AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced the presentation of new scientific data from its ARISE Phase III clinical outcomes study of its lead oral anti-diabetic drug candidate, AGI-1067, at the European Society of Cardiology Congress 2007. The data were...
New Data on AtheroGenics AGI-1067 Accepted for Presentation at the European Society of Cardiology Congress 2007
AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that new scientific data of its oral antidiabetic agent AGI-1067 has been accepted for an oral presentation in a Hotline & Clinical Update session at the upcoming European Society of Cardiology ESC Congress...
Wednesday Morning Stock Watch: BTEM! May 23, 2007
Stock Market Alerts' performance stock list includes: BioStem, Inc. (OTCBB: BTEM), MGM Mirage Inc. (NYSE: MGM), AtheroGenics Inc (NASDAQ: AGIX), Citrix Systems, Inc. (NASDAQ: CTXS). BioStem, Inc. (OTCBB: BTEM) is on the move and continues to issue good news, which should be of interest to investors. The company issued...
AtheroGenics to Present at Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2007
AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced its participation in the upcoming 2007 Morgan Stanley Global Healthcare Conference on Wednesday, May 2, 2007, at 3:45 p.m. EDT at The Ritz-Carlton in Key Biscayne, Florida. The conference will feature its...
- Next »
- page 1 of 2
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- Nasdaq Stock Market Inc. (17 results)
- FINANCE (13 results)
- Company (12 results)
- stock (10 results)
- Investment (10 results)
- HEALTHCARE (6 results)
- E-mail (5 results)
- Morgan Stanley (4 results)
- SOFTWARE (4 results)
- New York Stock Exchange (4 results)
- patient (3 results)
- Benefits (3 results)
- INTERNET (3 results)
- SEC (3 results)
- Incorporated: 1993
- CEO: Dr. Russell M. Medford M.D., Ph
- Employees: 57
AtheroGenics is a research-based pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease. As of Dec 31 2007 Co. has one late stage clinical drug development program. AGI-1067 is Co.'s investigational oral drug with demonstrated anti-inflammatory and antioxidant properties that is being studied to determine its ability to improve glycemic control in patients with diabetes and potentially reduce clinical events in patients with coronary heart disease.
Key Competitors
Industry Transcripts by Seeking Alpha
-
Indevus Pharmaceuticals, Inc. F4Q08 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 25, 2008about IDEV
-
Noven Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about NOVN
-
XenoPort, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about XNPT
-
Repligen Corporation F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 24, 2008about RGEN
-
Omrix Biopharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about OMRI
AtheroGenics Inc. Company Info
Board of Directors
Mr. Michael A. Henos
Chairman
Dr. Russell M. Medford M.D., Ph
Dr. R. Wayne Alexander M.D., Ph
Dr. Samuel L. Barker Ph.D.
Ms. Margaret E. Grayson
Contact Information
8995 Westside Parkway
Alpharetta, GA
678 336-2500
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
